GLP-1 side effects: what patients should monitor
Nausea may be common, but not every symptom is routine. A good plan explains what to expect, what to track, and when to call.
At a glance
Common side effects of GLP-1 medicines include nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, and fatigue, although the exact profile differs by drug. Gradual titration, hydration, adequate nutrition, and clinician follow-up can help. Severe or persistent abdominal pain, repeated vomiting, dehydration, allergic symptoms, or concerning new symptoms require prompt medical advice.
In this guide6 sections
The common effects are mostly gastrointestinal
GLP-1 and related incretin medicines slow stomach emptying, affect appetite, and influence glucose regulation. Nausea, diarrhea, vomiting, constipation, abdominal pain, bloating, indigestion, and reflux are commonly reported. Headache, dizziness, and fatigue can also occur with some products.1
The exact drug label matters. Side effects, contraindications, approved indications, and warnings are not interchangeable across every medicine grouped under the GLP-1 label.
- Track symptom severity and timing
- Record fluid and food tolerance
- Follow the exact titration schedule
- Tell the clinician about other glucose-lowering drugs
- Do not copy dose instructions from another product
Hydration and nutrition deserve active monitoring
Vomiting, diarrhea, and very low intake can cause dehydration and may contribute to kidney injury.1 Patients who cannot keep fluids down or who develop signs of dehydration should contact a clinician promptly.
The 2025 multi-society advisory on nutrition during GLP-1 therapy recommends screening for nutritional risk, managing gastrointestinal symptoms, and supporting adequate protein, micronutrients, and physical activity.2 Treatment should not reduce intake so far that health and function deteriorate.
Know the warning symptoms
Drug labels include warnings for problems such as pancreatitis, gallbladder disease, kidney injury from volume depletion, serious hypersensitivity, and other product-specific risks.1 Severe, persistent abdominal pain, especially if it travels to the back or occurs with vomiting, needs prompt evaluation.
Before surgery or deep sedation, patients should tell the care team they use a GLP-1 medicine because delayed stomach emptying can affect aspiration risk.1 Pregnancy plans, diabetes medicines, and a history of relevant endocrine, gastrointestinal, pancreatic, gallbladder, or kidney conditions should be reviewed with the prescriber.
Compounded products require additional caution
FDA-approved drugs are reviewed for safety, effectiveness, quality, and labeling. Compounded drugs are not FDA-approved. FDA has reported dosing errors, misleading labels, shipping problems, and other concerns with unapproved compounded GLP-1 products.3
FDA says compounded GLP-1 drugs should be used only when a patient’s medical need cannot be met by an approved drug.3 Patients should receive a prescription from a licensed clinician and use a properly licensed pharmacy, with exact instructions for the product’s concentration and volume.
Common questions
What are the most common GLP-1 side effects?
Nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, and fatigue are common with several GLP-1 medicines. The exact list and frequency differ by drug.
When should I call a clinician about GLP-1 side effects?
Call promptly for severe or persistent symptoms, repeated vomiting, inability to keep fluids down, signs of dehydration, severe abdominal pain, allergic symptoms, or any rapidly worsening concern.
Can I lower my dose on my own?
No. Dose and titration changes should be discussed with the prescriber and must match the exact medicine, device, and formulation.
Are compounded GLP-1 drugs FDA-approved?
No. Compounded drugs are not FDA-approved. FDA recommends approved products when they can meet the patient’s need and has warned about dosing and quality problems with unapproved versions.
References
- Source 1: FDA: Wegovy prescribing information (opens in a new tab)
- Source 2: Joint advisory: Nutritional priorities to support GLP-1 therapy (opens in a new tab)
- Source 3: FDA: Concerns with unapproved GLP-1 drugs used for weight loss (opens in a new tab)
A number in the text links to the source for that statement.
This guide provides general educational information and is not medical advice, diagnosis, or treatment. Treatment decisions require an appropriately licensed clinician who understands your history and circumstances.
Images are illustrations, not Everdawn members or clinicians.